Drug intelligence / Profile preview

PBK_M2101

Development stage: Phase 3
Lead developer: Pharmbio Korea
Administration: Oral

Overview

**PBK_M2101** is an investigational Pharmbio Korea drug product being evaluated as an oral bowel-preparation regimen before colonoscopy. In the registered Phase 3 study NCT05923918, PBK_M2101 is administered using either a 1-day or 2-day regimen and is compared with a 2-day oral sulfate tablet regimen. Public trial records do not disclose the product's precise active-ingredient composition, formulation, or a molecular target; it is therefore best characterized as an investigational colon-cleansing preparation rather than as a targeted therapeutic agent.

Beyond the preview

Go deeper on PBK_M2101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBK_M2101.

Explore the full profile